Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia.
The last earnings update was 97 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Nanollose. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Nanollose's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nanollose has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Nanollose's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Nanollose's earnings growth to the Australia market average as no estimate data is available.
Unable to compare Nanollose's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if Nanollose is high growth as no earnings estimate data is available.
Unable to determine if Nanollose is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Nanollose's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Raffaele Germano, also known as Alfie, has been Managing Director of Nanollose Limited since August 9, 2017 and also serves as its Chief Executive Officer. Mr. Germano is responsible for the operations of Nanollose Limited and development of the Nanollose Technologies. He is a creative achiever who strives for the balance of art and science in product and process. He is a 30-year veteran in the global textile industry sector. He served as Vice President and Director positions at GAP Inc, VF Corporation, Liz Claiborne Inc, Fila Inc and Carter's Inc. He worked with Armani and Gucci. He has travelled the world extensively with postings in the USA, Japan and China. He has served as Vice President for Global Manufacturing of Nonee I, LLC since October 2003. He had overseen the operations of overseas manufacturing facilities. Mr. Germano joined Nonee I in 1996 and served as its Product Manager. He spent 24 years in the garment industry as a leader of large scale global product development, sourcing and retail operations. He worked for his family garment manufacturing company. He has been Director of Nanollose Limited since August 9, 2017. He obtained his Fashion Design and Textile Science Diploma from the Bentley College of Technical and Further Education in Perth, Western Australia.
Insufficient data for Alfie to compare compensation growth.
Alfie's remuneration is about average for companies of similar size in Australia.
CEO, MD & Director
Executive Director of R&D and Executive Director
Board of Directors
CEO, MD & Director
Executive Director of R&D and Executive Director
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Nanollose insiders in the past 3 months, but not in substantial volumes.
Do Institutions Own Nanollose Limited (ASX:NC6) Shares?
Insider Ownership Of Nanollose The definition of company insiders can be subjective, and does vary between jurisdictions. … Private Company Ownership Our data indicates that Private Companies hold 9.1%, of the company's shares. … Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual.
Did You Manage To Avoid Nanollose's (ASX:NC6) 46% Share Price Drop?
Investors in Nanollose Limited (ASX:NC6) have tasted that bitter downside in the last year, as the share price dropped 46%. … There is almost always a chance they will need to raise more capital, and their progress - and share price - will dictate how dilutive that is to current holders. … With the share price down 46% in the last year, it seems likely that the need for cash is weighing on investors' minds.
What Kind Of Shareholder Owns Most Nanollose Limited (ASX:NC6) Stock?
The big shareholder groups in Nanollose Limited (ASX:NC6) have power over the company. … Generally speaking, as a company grows, institutions will increase their ownership. … Our analysis of the ownership of the company, below, shows that.
Is Nanollose Limited (ASX:NC6) A Financially Sound Company?
Nanollose Limited (ASX:NC6), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is NC6 will have to follow strict debt obligations which will reduce its financial flexibility. … Does NC6's growth rate justify its decision for financial flexibility over lower cost of capital.
This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Private Company Ownership Potential investors in NC6 should also look at another important group of investors: private companies, with a stake of 8.97%, who are primarily invested because of strategic and capital gain interests.
Unsuprisingly, this is below the growth rate of the Australian stock market as a whole. … This means it is an attractive growth stock relative to the wider Australian stock market. … ASX:NC6 PE PEG Gauge Feb 11th 18 The biotech industry is trading at a PE ratio of 27.6x, higher than the rest of the Australian stock market PE of 17.06x.
Breaking Down Nanollose Limited's (ASX:NC6) Ownership Structure
When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Check out our latest analysis for Nanollose ASX:NC6 Ownership_summary Jan 23rd 18 Insider Ownership Another important group of shareholders are company insiders. … Insider ownership has to do more with how the company is managed and less to do with the direct impact of the magnitude of shares trading on the market.
Should You Invest In The Healthcare Stock Nanollose Limited (ASX:NC6)?
However, this rate came in below the growth rate of the Australian stock market as a whole. … In the previous year, the industry saw growth of 9.22%, beating the Australian market growth of 5.37%. … ASX:NC6 PE PEG Gauge Nov 7th 17 The biotech industry is trading at a PE ratio of 27x, higher than the rest of the Australian stock market PE of 17x.
This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … Such level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Private Company Ownership Another important group of owners for potential investors in NC6 are private companies that hold a stake of 3.60% in NC6.
Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It focuses on the development of Nullarbor, a plant-free viscose-rayon fibre; and a commercial supply chain of microbial cellulose from various waste streams. Its products are used in textile, clothing, and other industries. Nanollose Limited has a collaborative research agreement with Umeå University, MoRe Research, and RISE Processum. The company was founded in 2014 and is based in Nedlands, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.